Literature DB >> 30314503

Identifying risk factors for recurrence of papillary thyroid cancer in patients who underwent modified radical neck dissection.

Young Jae Ryu1, Jin Seong Cho1, Jung Han Yoon1, Min Ho Park2.   

Abstract

BACKGROUND: Papillary thyroid cancer (PTC) patients with ipsilateral neck metastatic lymph node (LN) and those with contralateral neck metastatic LN belong to N1b. Only a few studies have reported on comparisons with regard to laterality of metastatic lateral LN. The aim of this study was to evaluate predictive factors for contralateral neck LN metastasis and to determine prognostic factors for recurrence in PTC patients with N1b.
METHODS: This retrospective study reviewed the medical records of 390 PTC patients who underwent total thyroidectomy and central LN dissection plus ipsilateral or bilateral modified radical neck dissection (MRND) between January 2004 and December 2012.
RESULTS: During a median follow-up of 81 (range, 6-156) months, 84 patients had a recurrence in any lesion. Male gender, a main tumor of more than 2 cm, number of metastatic central LN, number of harvested and metastatic lateral LN, total LN ratio, multifocality, bilaterality, and gross ETE had significance in the patients who underwent bilateral MRND. In multivariate analysis according to recurrence, patients with LN ratio > 0.44 in the central compartment (hazard ratio [HR], 1.890; 95% confidence interval [CI], 1.124-3.178; p = 0.015), LN ratio > 0.29 in the lateral compartment (HR, 2.351; 95% CI, 1.477-3.743; p < 0.001), and multifocality (HR, 1.583; 95% CI, 1.030-2.431; p = 0.036) were associated with worse RFS. However, the type of MRND was statistically significant only in univariate analysis.
CONCLUSIONS: Recurrence in N1b PTC patients is predicted by central neck LN ratio > 0.44, lateral neck LN ratio > 0.29, and multifocality of tumors. We suggest that patients with these factors should receive short-term follow-up using image modalities like ultrasonography and computed tomography.

Entities:  

Keywords:  Modified radical neck dissection; Papillary thyroid cancer; Recurrence

Mesh:

Year:  2018        PMID: 30314503      PMCID: PMC6186061          DOI: 10.1186/s12957-018-1496-1

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


Background

Papillary thyroid carcinoma (PTC) is the most common histologic type of thyroid cancer, and its incidence has been increasing worldwide. The prognosis for PTC is better than for other types of thyroid cancer; however, the involvement of lymph nodes (LNs) is up to 80% at diagnosis [1]. It is generally accepted that the spread pattern of LN in PTC is central compartment, ipsilateral compartment, and contralateral compartment sequentially. Although the most common location of LN involvement is the central compartment, skip metastasis (lateral LN metastasis without central LN metastasis) may be observed [2]. The definition of regional LN distinguishes between N1a (levels VI, VII) and N1b (levels I, II, III, IV, V, or retropharyngeal nodes); nevertheless, recent TNM staging did not consider the location of LN involvement [3]. The size of metastatic lateral LNs in surgical specimens is often bigger than is seen with metastatic central LN; however, it is not clear whether or not the reason behind poor outcomes for PTC patients with N1b is location, size, or number of metastatic LN. Several studies revealed that patients with pathologic N1b had a worse prognosis than those with pathologic N1a [4-6]. In addition, some authors reported that the patients with N1b disease had poorer disease-specific survival than those with N0 or N1a and the cause of death is due to distant metastasis rather than locoregional metastasis [7]. There is still debate around performing prophylactic central LN dissection for clinically LN negative PTC patients; however, it is not acceptable performing prophylactic lateral LN dissection for PTC patients without clinical N1b disease. According to recent American Thyroid Association (ATA) guidelines, comprehensive modified radical neck dissection (MRND) encompassing levels II–V was recommended for patients who were clinically N1b [8]. Few studies have compared clinocopathologic characteristics between ipsilateral MRND and bilateral MRND. Ohshima et al. reported that patients who underwent thyroidectomy and bilateral MRND had better 10-year survival rate (97.1% vs. 83.7%) and lower cancer death (5.8% vs. 28.1%) than those who underwent thyroidectomy and ipsilateral MRND [9]. On the other hand, Ito et al. revealed that N1b PTC patients, regardless of type of MRND, with metastatic lateral LNs smaller than 3 cm, with less than five metastatic lateral LNs, or without extranodal extension had similar survival outcomes compared with those N1a PTC patients [10]. The potential for detecting suspicious lateral LN with ultrasonography (US) and computed tomography (CT) is higher than that of central LN [11]. However, if suspicious contralateral LN remains, then residual or persistent disease can have potential effects on postoperative management. Thus, the aim of this study was to evaluate predictive factors for contralateral LN metastasis in PTC patients who underwent total thyroidectomy and central LN dissection, plus ipsilateral or bilateral MRND. Also, we wished to determine prognostic factors for recurrence in PTC patients with N1b.

Methods

Patients’ population

We reviewed the medical records of 9135 patients who underwent thyroid surgery at Chonnam National University Hwasun Hospital between January 2004 and December 2012. Exclusion criteria were as follows: patients who had less than a 6-month follow-up period, who underwent reoperation due to suspicious residual tumor or LN within 6 months of initial surgery, who underwent thyroid surgery for reasons other than PTC, who had discordant histology between thyroid tumor and LN on the pathologic report, who did not undergo comprehensive LN dissection in the lateral neck compartment, who had only contralateral lateral metastatic LN, who did not undergo thyroidectomy and MRND concurrently, who did not achieve R0 resection, who had secondary malignancy during follow-up, who had distant metastasis at initial diagnosis, and who had abnormal thyroid function test before first surgery. We enrolled a total 390 patients who underwent total thyroidectomy and central LN dissection plus ipsilateral or bilateral MRND in this study. This retrospective study was approved by the institutional review board in our hospital.

Operation

All patients were examined by neck US and neck CT during preoperative evaluation to scheme surgical extent, and especially to check the lateral neck compartment. We performed prophylactic central neck dissection, while MRND was not performed in the case of absence of evidence in the lateral compartment. When suspicious lateral LN was detected, fine needle aspiration cytology (FNAC) revealed the presence of absence of LN metastasis. However, in cases of uncertainty with FNAC, we performed an excisional frozen biopsy during the operation to proceed with MRND. Therefore, all patients in this study underwent therapeutic MRND. The performed surgeries included total thyroidectomy, central neck dissection, and MRND in a sequential manner. Central neck refers to level VI (pretracheal, paratracheal, prelaryngeal) or level VII (upper mediastinal LN). MRND refers to comprehensive excision of neck levels II–V with preservation of more than one in three structures: spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle. Level I dissection was not performed because it is a rare event and preoperative image modalities did not detect suspicious level I LN in enrolled patients. The boundary of LN levels were divided by operator and sent to the department of pathology. All patients were inserted with a drain after procedure.

Histopathologic examination

Surgical specimens were examined by more than two experienced pathologists. The main tumor was defined as the largest tumor. The laterality of ipsilateral MRND was consistent with the location of the main tumor. LN ratio was defined as the number of metastatic LN divided by the number of harvested LN, and skip metastases was indicated lateral LN metastasis without central LN metastasis. TNM stage and ETE were reclassified according to recent American Joint Committee on Cancer (AJCC) recommendations [3].

Postoperative follow-up

All patients received 30–100 mCi of radioactive iodine therapy 2–3 months after surgery because most patients had the possibility of more than an intermediate risk of structural disease recurrence according to recent ATA management guidelines. The patients were followed up every 3 to 6 months for 5 years and annually thereafter, if exhibiting no evidence of disease. All patients also received regular physical examination, neck US, chest radiography, whole-body iodine scanning, measurement of serum-free thyroxine, thyrotropin, thyroglobulin (Tg), and anti-thyrogobulin antibody concentrations. We defined recurrence as structural recurrence. Locoregional recurrence was confirmed by FNAC based on the result of imaging modalities such as neck US, neck CT, 18F-fluorodeoxyglucose positron emission tomography CT, and whole-body scan. Distant metastasis was confirmed by the abovementioned imaging modalities. Most patients with structural recurrence underwent reoperation; however, if the patients had an unresectable lesion or distant metastasis, radioactive iodine therapy was considered as a first option.

Complications

Hypoparathyroidism and recurrent laryngeal nerve palsy were classified as transient or permanent based on 6 months after surgery. We defined hypoparathyroidism as postoperative serum parathyroid hormone level below normal, with a concomitant low calcium level and requiring calcium and vitamin D supplementation. Patients who underwent thyroid surgery in our institution underwent examination for the level of PTH in 6 h, 24 h, and 48 h postoperatively. Patients who had a lower level of PTH were checked every 2 days during admission. The level of PTH was examined with the level of total calcium and ionized calcium. We considered recurrent laryngeal nerve palsy through flexible laryngoscopy as well as voice change after surgery. All patients in this study were not routinely examined via preoperative laryngoscopy. However, patients who had suspicious gross ETE into posterior surface of the thyroid or trachea or who had symptoms related with voice change underwent preoperative laryngoscopy. Postoperative laryngoscopy was performed selectively for patients who had preoperative experience and with symptoms regarding voice change, or with suspicion of recurrent laryngeal nerve injury. Postoperative bleeding was defined as the case which underwent the operation, and chyle leakage was defined as the case which underwent operative or conservative management.

Statistics

Disease-specific mortality was a rare event. Therefore, the primary end point was recurrence in any lesion. We defined recurrence-free survival (RFS) as the time between the first operation and confirmation of recurrence. Continuous variables are represented as median (range) or mean (standard deviation, SD), while categorical variables are shown as a number (percent). Independent t test and chi-square analysis were used to compare between ipsilateral MRND and bilateral MRND. A univariate Cox proportional hazards model was used to analyze the relationship between clinicopathologic variables and recurrence-free survival. Multivariate Cox proportional hazards regression analyses by way of backward elimination were performed using the variables with p values < 0.05 in the univariate analyses. The receiver operating characteristic curve was used to calculate optimal value of LN ratio in the central and the lateral compartment. We used the log-rank test and the Kaplan-Meier curve to calculate differences in RFS. We performed all statistical analyses using SPSS version 23.0 (IBM Inc., Armonk, NY, USA) and defined statistical significance as p less than 0.05.

Results

Patients’ demographics

Of a total 390 patients, median age (range) was 46 years (17–80) and 118 patients (30.3%) were male. Patients who underwent ipsilateral MRND and bilateral MRND were 346 (88.7%) and 44 (11.3%), respectively. Mean (SD) size of the main tumor was 1.61 cm (± 0.97) and patients in which the main tumor was more than 2 cm were 93 (23.8%). Findings for T stage were as follows: T1a, 121 patients (31.0%); T1b, 109 (27.9); T2, 40 (10.3%); T3a, 4 (1.0%), T3b, 52 (13.3%); and T4a, 64 (16.4%). One hundred forty-two (36.4%) and 125 (32.1%) patients had multifocality and bilaterality of tumors. Seventy-five (19.2%) patients had minor ETE, and 116 (29.7%) patients had gross ETE of the main tumor. Mean (SD) number of harvested central LN and metastatic central LN were 7.4 (± 6.0) and 3.8 (± 4.0). Mean (SD) number of harvested central LN and metastatic lateral LN were 18.6 (± 10.3) and 4.9 (± 3.9). Skip metastasis showed in 86 (22.1%) patients. Patients with stage I were 285 (73.1%); stage II, 79 (20.3%); and stage III, 26 (6.7%). We observed chronic lymphocytic thyroiditis (CLT) in 100 (25.6%) while 20 (5.1%) patients showed lymphovascular invasion (LVI). Median follow-up was 81 (range, 6–156) months (Table 1).
Table 1

Patients’ demographics

VariablesNumber (%)
Age (years)§46 (17–80)
 ≤ 55 years285 (73.1)
Male118 (30.3)
Hypertension62 (15.9)
Diabetes26 (6.7)
Modified radical neck dissection
 Ipsilateral346 (88.7)
 Bilateral44 (11.3)
Main tumor size (cm)*1.61 ± 0.97
 > 2 cm93 (23.8)
T stage
 T1a121 (31.0)
 T1b109 (27.9)
 T240 (10.3)
 T3a4 (1.0)
 T3b52 (13.3)
 T4a64 (16.4)
Multifocality142 (36.4)
Bilaterality125 (32.1)
Extrathyroidal extension
 No199 (51.0)
 Minor75 (19.2)
 Gross116 (29.7)
Number of central lymph node
 Harvested§, *6 (2–65), 7.4 ± 6.0
 Metastatic§, *3 (0–29), 3.8 ± 4.0
Number of lateral lymph node
 Harvested§, *16 (8–62), 18.6 ± 10.3
 Metastatic§, *4 (1–23), 4.9 ± 3.9
Skip metastases86 (22.1)
Stage
 I285 (73.1)
 II79 (20.3)
 III26 (6.7)
Lymphovascular invasion20 (5.1)
Chronic lymphocytic thyroiditis100 (25.6)
Recurrence84 (21.5)
Follow-up§81 months (6–156)
Total patients390

§Median and range

*Mean and standard deviation

Patients’ demographics §Median and range *Mean and standard deviation

Recurrence

Eighty-four (21.5%) patients demonstrated recurrence during the follow-up period. Among the 33 patients with recurrence in the central compartment or operative bed, 12 patients had recurrence in the lateral compartment; 1 patient, in the distant lesion; and 1 patient, in the lateral compartment and distant lesion. Forty-eight patients had recurrence only in the lateral compartment. Three patients showed only distant metastasis. The most common organ of distant metastasis is the lung (4 patients) followed by the bone (1 patient) (Table 2). Of 84 patients who had a recurrence, 79 (94.0%) patients had a recurrence within 5 years after surgery.
Table 2

Distribution of recurrence site

Number
Central LN or operative bed33
 Only central LN or op bed19
 + Lateral LN12
 + Distant metastasis1
 + Lateral LN + distant metastasis1
Only lateral LN48
Only distant metastasis3

LN lymph node

Distribution of recurrence site LN lymph node

Comparison according to MRND type

Between patients who underwent unilateral MRND and the patients with bilateral MRND, male gender, larger than a 2 cm main tumor, number of metastatic central LN, number of harvested and metastatic lateral LN, total LN ratio, multifocality, bilaterality, and gross ETE had significance in patients who underwent bilateral MRND. There was no statistical association with age, CLT, LVI, and TNM stage (Table 3).
Table 3

Comparison of MRND type and clinicopathologic characteristics

VariablesIpsilateral MRNDBilateral MRND p
N = 346N = 44
Age46.2 ± 13.348.1 ± 15.60.369
 ≤ 55 years255 (73.7)30 (68.2)0.471
 > 55 years91 (26.3)14 (31.8)
Sex< 0.001
 Female252 (72.8)20 (45.5)
 Male94 (27.2)24 (54.5)
Main tumor size (cm)1.54 ± 0.912.20 ± 1.21< 0.001
 ≤ 2 cm272 (78.6)25 (56.8)0.002
 > 2 cm74 (21.4)19 (43.2)
Number of central lymph node
 Harvested7.2 ± 5.98.4 ± 6.20.210
 Metastatic3.4 ± 3.56.3 ± 6.0< 0.001
Number of lateral lymph node< 0.001
 Harvested16.6 ± 8.133.6 ± 13.3< 0.001
 Metastatic4.2 ± 2.910.5 ± 5.5
Skip metastases80 (23.1)6 (13.6)0.179
LN ratio0.34 ± 0.190.41 ± 0.210.012
Multifocality114 (32.9)28 (63.6)< 0.001
Bilaterality101 (29.2)24 (54.5)0.001
ETE0.003
 No/minor252 (72.8)22 (50.0)
 Gross94 (27.2)22 (50.0)
CLT92 (26.6)8 (18.2)0.274
LVI16 (4.6)4 (9.1)0.263
Stage0.406
 I255 (73.7)30 (68.2)
 II70 (20.2)9 (20.5)
 III21 (6.1)5 (11.4)
Recurrence67 (19.4)17 (38.6)0.006

MRND modified lateral neck dissection, LN lymph node, ETE extrathyroidal extension, CLT chronic lymphocytic thyroiditis, LVI lymphovascular invasion

Comparison of MRND type and clinicopathologic characteristics MRND modified lateral neck dissection, LN lymph node, ETE extrathyroidal extension, CLT chronic lymphocytic thyroiditis, LVI lymphovascular invasion

Uni- and multivariate analyses according to recurrence

In univariate analysis of associations with recurrence, larger than 2 cm main tumor (p = 0.025), LN ratio > 0.44 in the central compartment (p < 0.001) and LN ratio > 0.29 in the lateral compartment (p < 0.001), bilateral MRND (p = 0.004), multifocality (p = 0.012), no CLT (p = 0.037), and gross ETE (p = 0.040) showed statistically significant differences. However, there were no differences in RFS with age, sex, skip metastasis, bilaterality, LVI, or stage (Table 4, Fig. 1a−c).
Table 4

Univariate analysis of risk factors for recurrence

Exp (B)95% CI for Exp (B) p
Age
 ≤ 55 years1
 > 55 years1.1380.713–1.8160.589
Sex
 Female1
 Male1.0370.653–1.6480.877
Main tumor size
 ≤ 2 cm1
 > 2 cm1.6891.068–2.6710.025
Skip metastasis
 No1
 Yes0.6960.392–1.2350.215
LN ratio (central)
 ≤ 0.441
 > 0.442.4921.508–4.118< 0.001
LN ratio (lateral)
 ≤ 0.291
 > 0.292.8221.799–4.426< 0.001
MRND type
 Ipsilateral1
 Bilateral2.1581.267–3.6760.004
Multifocality
 No1
 Yes1.7351.131–2.6620.012
Bilaterality
 No1
 Yes1.5140.981–2.3370.061
CLT
 NO1
 Yes0.5420.305–0.9620.037
ETE
 No/minor1
 Gross1.5831.022–2.4530.040
LVI
 No1
 Yes1.0970.444–2.7080.841
Stage
 I1
 II0.9520.548–1.6540.862
 III1.7400.863–3.5090.122

CI confidence interval, LN lymph node, MRND modified radical neck dissection, CLT chronic lymphocytic thyroiditis, ETE extrathyroidal extension, LVI lymphovascular invasion

Fig. 1

Kaplan-Meier curves according to CLN ratio (a), LLN ratio (b), and multifocality (c). CLN central neck lymph node, LLN lateral neck lymph node

Univariate analysis of risk factors for recurrence CI confidence interval, LN lymph node, MRND modified radical neck dissection, CLT chronic lymphocytic thyroiditis, ETE extrathyroidal extension, LVI lymphovascular invasion Kaplan-Meier curves according to CLN ratio (a), LLN ratio (b), and multifocality (c). CLN central neck lymph node, LLN lateral neck lymph node In multivariate analysis, LN ratio > 0.44 in the central compartment (vs. ≤ 0.44; hazard ratio [HR], 1.890; 95% confidence interval [CI], 1.124–3.178; p = 0.015), LN ratio > 0.29 in the lateral compartment (vs. ≤ 0.29; HR, 2.351; 95% CI, 1.477–3.743; p < 0.001), and multifocality (vs. no multifocality; HR, 1.583; 95% CI, 1.030–2.431; p = 0.036) were associated with worse RFS (Table 5).
Table 5

Multivariate analysis of risk factors for recurrence

Exp (B)95% CI for Exp (B) p
Main tumor size
 ≤ 2 cm1
 > 2 cm1.4800.931–2.3550.098
LN ratio (central)
 ≤ 0.441
 > 0.441.8901.124–3.1780.016
LN ratio(lateral)
 ≤ 0.291
 > 0.292.3511.477–3.743< 0.001
Multifocality
 No1
 Yes1.5831.030–2.4310.036
CLT
 No1
 yes0.6440.362–1.1490.136
MRND type
 Ipsilateral1
 Bilateral1.3350.744–2.3940.332
ETE
 No1
 Gross1.3080.824–2.0760.255

CI confidence interval, LN lymph node, CLT chronic lymphocytic thyroiditis, MRND modified radical neck dissection, ETE extrathyroidal extension

Multivariate analysis of risk factors for recurrence CI confidence interval, LN lymph node, CLT chronic lymphocytic thyroiditis, MRND modified radical neck dissection, ETE extrathyroidal extension

Postoperative complications

Of the 390 patients, the incidence of transient and permanent hypoparathyroidism were 16 (4.1%) and 3 (0.8%) patients, respectively. We observed transient and permanent recurrent laryngeal nerve palsy in 23 (5.9%) and 14 (3.6%) patients (Table 6). Among 29 patients with invasion to recurrent laryngeal nerve, 24 patients underwent shaving operation and 5 patients underwent re-anastomosis of recurrent laryngeal nerve; no patients underwent concurrent tracheostomy. Two patients underwent reoperation due to postoperative bleeding during admission after initial surgery; two patients showed chyle leakage, one of these patients underwent operative treatment and the remaining patient recovered after conservative management.
Table 6

Postoperative complications

Number (%)
Hypoparathyroidism
 Transient16 (4.1)
 Permanent3 (0.8)
Recurrent laryngeal nerve injury
 Transient23 (5.9)
 Permanent14 (3.6)
Postoperative bleeding2 (0.5)
Chyle leakage2 (0.5)
Postoperative complications

Discussion

Among PTC patients with N1b in this study, 44 (12.7%) had contralateral neck metastatic LNs. Contralateral neck LN metastasis was associated with male gender, more than 2 cm size of main tumor, a high number of metastatic central LN, multifocality and bilaterality of the tumors, and gross ETE. However, there was no significant relationship between type of MRND (ipsilateral MRND vs. bilateral MRND) and recurrence. LN ratio in central and lateral compartment, and multifocality of tumors were independent prognostic factors in N1b PTC patients. According to ATA guidelines, prophylactic central LN dissection should be considered in patients with clinically central node-negative who have advanced primary tumors (T3 or T4) or clinically N1b [8]. However, prophylactic MRND is not recommended if the patients had no evidence of FANC or Tg washout measurement in the lateral compartment [8]. The sensitivity of US detection of lateral neck LN is higher than that of central LN [11]. Meticulous evaluation of lateral neck LN using US is needed for PTC patients during the preoperative evaluation period. In a study of 135 PTC patients who underwent bilateral neck dissection, the authors found that bilaterality of tumors and tumors arising in the isthmus were associated with bilateral LN metastasis [12]. They also demonstrated that contralateral neck LN metastasis was significantly correlated with clinically node-positive in the ipsilateral neck and contralateral paratracheal LN metastasis. In another study of 1776 PTC patients who underwent thyroidectomy and ipsilateral MRND during mean follow-up of 12.1 years, 32 (1.8%) patients recurred with contralateral neck LN [13]. They concluded that risk factors for contralateral neck LN were male gender, more than 2 cm size of primary tumor, ETE, and the presence of gross nodal metastasis at the initial surgery. Therefore, they suggested that patients with the abovementioned factors may be recommended for bilateral MRND. Although N1b PTC patients with a high number of metastatic central LN, multifocality, or bilaterality, as well as those with bigger tumor or gross ETE, tended to have contralateral neck LN metastasis in this study, further study is needed to demonstrate the execution of both MRND. Several studies revealed that the number of metastatic LN at diagnosis were associated with recurrence in PTC [1, 14]. In addition, some studies found that LN ratio (the number of metastatic LN divided by the number of harvested LN) is related to post-treatment recurrence. A study of 198 PTC patients who underwent total thyroidectomy and neck dissection concluded that patients with LN ratio ≥ 0.3 had 3.4 times higher risk of persistent or recurrent disease than did those with ratio of 0 [15]. Schneider et al. reported that patients with LN ratio more than 0.7 showed significantly worse disease-free survival rates compared with those with ratio below 0.7 [16]. However, Lee et al. reported that central plus lateral LN ratio did not have an association with recurrence in patients who underwent therapeutic central and lateral neck dissection [17]. The present study separated LN status based on the location of metastatic LN: central compartment or lateral compartment. Skip metastasis, N1b without central LN metastasis, was not associated with recurrence. LN ratio > 0.44 in the central compartment and LN ratio > 0.29 in the lateral compartment were independent prognostic factors for poor RFS in patients with N1b disease. Even though the LN ratio in PTC is a useful prognostic factor for disease-free survival, multicenter studies are required to set optimal cutoffs, standardize the number and surgical extent, and supplement TNM staging. Shattuck et al. described that individual tumor foci in multifocal PTC originate from discrete tumors independently [18]. Another study demonstrated that multifocal PTC stems from the same clone; therefore, it is important for intrathyroidal metastasis in PTC [19]. Although the reason of multifocality in PTC is not clear, multifocal PTC is not a rare event. Indeed, there is still controversy regarding multifocality in PTC and survival outcomes. Some study has reported that multifocality is not associated with recurrence [20]. Another study showed that bilaterality rather than unilateral multifocality of PTC was proven to be an independent risk factor for locoregional recurrence, distant metastasis, and cancer death [21]. On the other hand, Lin et al. revealed that multifocal PTC patients have higher recurrence rate and advanced TNM stage compared to solitary PTC patients [22]. Also, some authors described that patients with multifocal micro PTC were observed to have 5.6-fold higher LN recurrence [23]. Another study showed that the number of multifocal tumors rather than the location is significant predictive factor for disease recurrence [24]. This study showed 36.4% multifocality and 32.1% bilaterality in patients with N1b. The patients who underwent bilateral MRND tended to have multifocality and bilaterality; however, only multifocality was related to RFS. ETE is an important prognostic factor for survival outcomes in PTC. In the sixth AJCC, ETE was classified as minor and gross [25]; however, according to recent AJCC recommendations, minor ETE was removed from the definition of T3 disease [3]. Therefore, tumors > 4 cm in greatest dimension limited to the thyroid gland is considered T3a and gross ETE with invasion only to the strap muscles is considered T3b [3]. This study did not include patients with T4b because complete resection was not achieved. The patients with gross ETE were associated with contralateral neck LN metastasis and poor RFS in univariate analysis; however, there was no statistically significance between gross ETE and RFS in multivariate analysis. CLT is an autoimmune disease characterized by fibrosis, atrophy, and lymphocyte infiltration in thyroid tissue. CLT exhibits a thyroid-specific antigen that is represented in thyroid tumor and may be involved in the destruction of thyroid cancer. Several investigations reported that PTC patients with coexisting CLT have lower recurrence rate and better overall survival due to control of tumor growth and proliferation [26, 27]. This study showed that patients with CLT have lower recurrence rates in univariate analysis; however, there is no relation between CLT and recurrence in multivariate analysis. In terms of the location of metastatic LN, Ito et al. revealed that the 621 N1b PTC patients with less than 3 cm metastatic lateral LN, less than five metastatic lateral LNs, or without extranodal extension had similar survival outcomes compared with those N1a PTC patients [10]. Several studies found that the location of metastatic LN rather than the number is useful for predicting risk of recurrence or distant metastasis; therefore, the distinction between N1a and N1b is extremely important for postoperative management in PTC patients [28, 29]. Even though the location of metastatic LN is not reflected in TNM stage, it is a powerful factor that affects disease-specific survival to decide the surgical extent. According to the ATA guidelines, neck US should be performed at 6–12 months after initial surgery and then periodically depending on the risk of recurrence and Tg status [8]. A considerable number of patients had a recurrence within 5 years in this study; thus, we suggest that patients who had undergone MRND should be checked via neck US every 6 months at least for 5 years. In addition, neck CT is useful for detection of especially suspicious central LNs. Therefore, we suggest that neck CT should be performed periodically for patients with negative neck US and high level of Tg. This study has several limitations. Study design was retrospective and conducted at a single institution. In order to determine laterality of lateral LN metastasis if the patients who underwent ipsilateral MRND had bilaterality of tumors, it was decided by the location of the bigger tumor. Therefore, selection bias is reflected in decisions regarding laterality. In addition, the decision of surgical extent might be intervened by interpretation of radiologists and surgeons of preoperative imaging modalities like neck US and neck CT. We did not consider patients with biochemical incomplete response that related to Tg and anti-Tg measurement. We are collecting more sufficient clinicopathological data for long-term follow-up of patients who underwent total thyroidectomy and MRND.

Conclusions

The patients who underwent ipsilateral MRND or bilateral MRND have the same N stage. The surgical extent of lateral neck compartment is not reflected in TNM stage. However, meticulous preoperative evaluation of contralateral LN is needed to avoid residual or persistent disease during postoperative follow-up. The factors that associated with contralateral LN metastasis were male gender, more than 2 cm size of main tumor, multifocality, bilaterality, and ETE. Recurrence in N1b PTC patients is predicted by central neck LN ratio > 0.44, lateral neck LN ratio > 0.29, and multifocality of tumors. We suggest that patients with these factors should receive short-term follow-up using image modalities like US and CT.
  27 in total

1.  Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas.

Authors:  Ryan P McCarthy; Mingsheng Wang; Timothy D Jones; Randall W Strate; Liang Cheng
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia.

Authors:  Soo Youn Cho; Tae Hyun Lee; Yun Hyi Ku; Hong Il Kim; Guk Haeng Lee; Min Joo Kim
Journal:  Surgery       Date:  2014-10-14       Impact factor: 3.982

3.  Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma.

Authors:  K Kashima; S Yokoyama; S Noguchi; N Murakami; H Yamashita; S Watanabe; S Uchino; M Toda; A Sasaki; T Daa; I Nakayama
Journal:  Thyroid       Date:  1998-03       Impact factor: 6.568

4.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

5.  Risk of bilateral cervical lymph node metastases in papillary thyroid cancer.

Authors:  M Noguchi; S Kinami; K Kinoshita; H Kitagawa; M Thomas; I Miyazaki; T Michigishi; Y Mizukami
Journal:  J Surg Oncol       Date:  1993-03       Impact factor: 3.454

6.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

7.  High recurrent rate of multicentric papillary thyroid carcinoma.

Authors:  Jen-Der Lin; Tzu-Chieh Chao; Chuen Hsueh; Sheng-Fong Kuo
Journal:  Ann Surg Oncol       Date:  2009-06-16       Impact factor: 5.344

8.  Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck.

Authors:  Chang Wook Lee; Jong-Lyel Roh; Gyungyup Gong; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Ann Surg Oncol       Date:  2014-07-18       Impact factor: 5.344

9.  Skip metastases in thyroid cancer leaping the central lymph node compartment.

Authors:  Andreas Machens; Hans-Jürgen Holzhausen; Henning Dralle
Journal:  Arch Surg       Date:  2004-01

10.  Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping.

Authors:  Yasuhiro Ito; Akira Miyauchi; Tomoo Jikuzono; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kiyoshi Ichihara; Kanji Kuma
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

View more
  7 in total

1.  Minimal extrathyroidal extension is associated with lymph node metastasis in single papillary thyroid microcarcinoma: a retrospective analysis of 814 patients.

Authors:  Ra-Yeong Song; Hee Sung Kim; Kyung Ho Kang
Journal:  World J Surg Oncol       Date:  2022-05-28       Impact factor: 3.253

2.  Predictive role of intraoperative clinicopathological features of the central compartment in estimating lymph nodes metastasis status.

Authors:  Rong-Hao Sun; Chao Li; Yu-Qiu Zhou; Yong-Cong Cai; Chun-Yan Shui; Wei Liu; Xu Wang; Din-Fen Zeng; Jian Jiang; Jing-Qiang Zhu
Journal:  Ann Transl Med       Date:  2019-09

3.  High rate of IIA/IIB neck groups involvement supports complete lateral neck dissection in thyroid carcinoma.

Authors:  Emilien Chebib; Caroline Eymerit; Nathalie Chabbert-Buffet; Bruno Angelard; Jean Lacau St Guily; Sophie Périé
Journal:  Gland Surg       Date:  2020-12

4.  Radical neck dissection with advancement flap in advanced papillary thyroid cancer: a therapeutic option.

Authors:  Alex Paul Guachilema Ribadeneira; Cristhian Ramiro García; Andrea Daniela Basantes
Journal:  J Surg Case Rep       Date:  2020-12-31

Review 5.  Papillary Thyroid Cancer Prognosis: An Evolving Field.

Authors:  Salvatore Ulisse; Enke Baldini; Augusto Lauro; Daniele Pironi; Domenico Tripodi; Eleonora Lori; Iulia Catalina Ferent; Maria Ida Amabile; Antonio Catania; Filippo Maria Di Matteo; Flavio Forte; Alberto Santoro; Piergaspare Palumbo; Vito D'Andrea; Salvatore Sorrenti
Journal:  Cancers (Basel)       Date:  2021-11-07       Impact factor: 6.639

Review 6.  Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis.

Authors:  Likun Cui; Dongdong Feng; Chaofan Zhu; Qiuyu Li; Wenqing Li; Baoguo Liu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-06-21

7.  Central Lymph Node Ratio Predicts Recurrence in Patients with N1b Papillary Thyroid Carcinoma.

Authors:  Il Ku Kang; Kwangsoon Kim; Joonseon Park; Ja Seong Bae; Jeong Soo Kim
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.